Professor in Psychiatry and Behavioral Sciences and Physiology, Northwestern University Medical School

Psychiatry

Herbert Meltzer practices Psychiatry. He studied medicine at Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine Doctor Herbert Meltzer, MD is a published doctor and has 101 publications published. The lastest was: 'Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens.'

Publications

---

• GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
• Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
• Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.
• Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition.
• Decreased serotonin2C receptor responses in male patients with schizophrenia.
• Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object r...
• Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.
• The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.
• The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.
• Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis.
• A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
• The Novel Object Recogniton Test in Rodents in Relation to Cognitive Impairment in Schizophrenia.
• Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
• Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism an...
• D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats.
• Update on typical and atypical antipsychotic drugs.
• The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia.
• Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine.
• Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.
• Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.
• Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
• Brain region effects of clozapine on amino acid and monoamine transmission.
• Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.
• Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia.
• Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
• Suicide in schizophrenia: risk factors and clozapine treatment.
• Clinical efficacy of clozapine in the treatment of schizophrenia.
• The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine.
• Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia.
• Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.
• Effect of clozapine on psychogenic polydipsia in chronic schizophrenia.
• Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat.
• Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens.
• Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response.
• Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes.
• Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response.
• Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia.
• Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.
• The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response.
• Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
• Risperidone in treatment of choreoathetosis of Huntington's disease.
• In vivo immunomodulatory effects of clozapine in schizophrenia.
• The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: ...
• Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.
• Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function.
• Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia.
• Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
• An atypical compound by any other name is still a.
• Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
• The role of serotonin receptors in the action of atypical antipsychotic drugs.
• Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia.
• Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation.
• Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.
• Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?
• Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens.
• Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission.
• Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major ...
• D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.
• R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not str...
• The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens.
• What''s atypical about atypical antipsychotic drugs?
• Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options.
• Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
• Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
• The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus.
• A novel augmentation strategy for treating resistant major depression.
• The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain.
• Serotonin receptors in suicide victims with major depression.
• Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.
• Stimulatory effects of L-5-hydroxytryptophan on postdexamethasone beta-endorphin levels in major depression.
• Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
• Brain noradrenergic receptors in major depression and schizophrenia.
• Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.
• Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients.
• Documenting an episode of psychiatric illness: need for multiple information sources, multiple raters, and narrative.
• What is schizophrenia?
• Schizoaffective disorder: is the news of its nonexistence premature? Editor's introduction.
• Assessment of negative and positive symptoms in schizophrenia.
• Biological studies of schizoaffective disorders.
• Treatment of schizoaffective disorders.
• Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies.
• Factors affecting determination of platelet monoamine oxidase activity.
• Brain and skeletal muscle monoamine oxidase activity in schizophrenia.
• The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements.
• Drugs and psychosocial treatment: editors' introduction.
• Biological studies in schizophrenia.
• The mechanism of action of novel antipsychotic drugs.
• Clinical services research.
• Treatment of the neuroleptic-nonresponsive schizophrenic patient.
• Physiologic abnormalities of the neuromuscular system in schizophrenia.
• The dopamine hypothesis of schizophrenia: a review.
• Neuromuscular dysfunction in schizophrenia.
• Biochemical studies in schizophrenia.
• Biology of schizophrenia subtypes: a review and proposal for method of study.
• Do anticholinergic antagonize antipsychotic drug action?
• The effect of apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and placebo on smooth pursuit gain and corrective saccades in normal subjects.
• Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis.
• Effect of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients.
• Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics.
• Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism.

Schools

---

• Yale University

• St LukeS Hospital

• Mass Mh Center

Doctors Specialties

---

• Psychiatry

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• Blue Card PPO
• Blue Cross Blue Shield of Illinois PPO
• Blue Network E
• Network S
• First Health (Coventry Health Care) PPO
• HealthLink PPO
• Choice Care PPO
• Medicare MCR
• MultiPlan PPO
• PHCS Network PPO
• United Healthcare

Education

---

• St Luke's-Roosevelt Hospital Center
• Yale University School of Medicine

Hospital

---

• Vanderbilt Hospital and Clinics
• Northwestern Memorial Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Charles R. Freed Jr., MD
	Dr. William S. West, MD
	Dr. Karyn Brown, MD This Doctor is OpenDoctor Recommended.
	Dr. Corey D. Campbell, DO
	Dr. Daniel D. Swartz, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael W. Franklin, MD
	Dr. Gladys A. Bush, MD This Doctor is OpenDoctor Recommended.
	Dr. Kathryn E. Jalovec, MD This Doctor is OpenDoctor Recommended.
	Dr. Judith J. Regan, MD This Doctor is OpenDoctor Recommended.
	Dr. Shahid S. Ali, MD
	Dr. Mariko D. Brandon, MD
	Dr. David K. Patzer, MD This Doctor is OpenDoctor Recommended.
	Dr. Lynna G. Hollis, MD
	Dr. Danica C. Denton, DO
	Dr. Chandra S. Krishnasastry, MD This Doctor is OpenDoctor Recommended.
	Dr. Saleh Ahmad, MD This Doctor is OpenDoctor Recommended.
	Sylvia A. Exum
	Dr. Barbara V. Wise, MD This Doctor is OpenDoctor Recommended.
	Dr. William G. Wood, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog